<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529149</url>
  </required_header>
  <id_info>
    <org_study_id>[2018]007</org_study_id>
    <nct_id>NCT03529149</nct_id>
  </id_info>
  <brief_title>TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT</brief_title>
  <official_title>TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesized that the precise regulation of blood pressure based on the changes
      of cerebral blood flow parameters under TCD monitoring can better improve the state of
      cerebral blood flow, reduce the risk of early neurological deterioration and improve the
      prognosis of the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early neurological deterioration</measure>
    <time_frame>72 hours</time_frame>
    <description>the incidence of 72 hours in National Institute of Health stroke scale increased more than 4 points or National Institute of Health stroke scale Ia score more than 1 points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prognosis of nerve function</measure>
    <time_frame>3 months</time_frame>
    <description>prognosis of nerve function use Modified Rankin Scale,0~3 is good prognosis and 4~6 is poor prognosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Accurate blood pressure control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implementing accurate blood pressure management under TCD monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline blood pressure control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control blood pressure according to guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Urapidil Hydrochloride Injection</intervention_name>
    <description>Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV&gt;37cm/s of （middle cerebral artery)MCA, PI &lt; 1.34cm/s, aMFV&gt;40cm/s of (basilar artery)BA, PI &lt; 0.8cm/s.
TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.</description>
    <arm_group_label>Accurate blood pressure control</arm_group_label>
    <arm_group_label>Guideline blood pressure control</arm_group_label>
    <other_name>Diltiazem Hydrochloride for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older;

          -  accept EVT treatment within 6 hours of symptoms onset;

          -  In selected patients with AIS within 6 to 16 hours of last known normal who have LVO
             in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria..

          -  In selected patients with AIS within 6 to 24 hours of last known normal who have LVO
             in the anterior circulation and meet other DAWN eligibility criteria.

        Exclusion Criteria:

          -  Pre - onset mRS&gt;2;

          -  severe dementia;

          -  threatening life diseases (such as malignant tumor, etc.);

          -  non acute ischemic cerebrovascular disease patients undergoing selective intravascular
             treatment;

          -  related sound window closure can not be monitoring with TCD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Yingying</last_name>
      <phone>15901361953</phone>
      <email>tangsuyingying@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urapidil</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

